skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treatment of retinal pigment epithelial detachment with antiangiogenic therapy

Original Research

(5008) Views  (1176) Full article downloads

Authors: Luis Arias

Published Date April 2010 Volume 2010:4 Pages 369 - 374
DOI: http://dx.doi.org/10.2147/OPTH.S9307

Luis Arias

Department of Ophthalmology, Bellvitge University Hospital, Barcelona, Spain

Purpose: Evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) associated with occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Methods: Prospective, comparative, nonrandomized pilot study included patients with PED comprising >50% of total lesion in subfoveal location with visual acuity (VA) 20/40–20/400 and lesions either previously untreated or treated only with photodynamic therapy/verteporfin. Seven patients received pegaptanib 0.3 mg intravitreally (IVT); eight received IVT bevacizumab 1.25 mg. Follow-up occurred every 4–6 weeks for 6 months. Reinjection of initial medication occurred if there was intra- or subretinal fluid observed by optical coherence tomography (OCT) or increased PED. Endpoints were mean changes from baseline to month 6 in VA (ETDRS) and foveal thickness.

Results: At baseline, mean VA was lower, and mean foveal thickness was greater in pegaptanib versus bevacizumab-treated patients (36.1 vs 49.5 letters; 470.4 vs 321.1 μm). Mean improvements to month 6 in VA and foveal thickness were greater for pegaptanib (VA: +9.1 vs +7.2 letters; foveal thickness: −88.2 vs −52.9 μm). On average, pegaptanib-treated patients had slower but more sustained improvement in VA and foveal thickness; bevacizumab-treated patients showed rapid improvement with a slow return towards baseline. Both agents were well tolerated.

Conclusion: Intravitreal injections of pegaptanib or bevacizumab are both efficacious and safe treatments for PED associated with occult CNV secondary to AMD.

Keywords: bevacizumab, pegaptanib, retinal pigment epithelial detachment






 

Other articles by Dr Luis Arias



Readers of this article also read:

Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Comparative studies of RNFL thickness measured by OCT with global index of visual fields in patients with ocular hypertension and early open angle glaucoma
Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?
Sequential spectral domain OCT documentation of retinal changes after branch retinal artery occlusion
Low-dose aspirin as treatment for central serous chorioretinopathy
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
23-gauge pars plana vitrectomy for management of posteriorly dislocated crystalline lens
Perfluorocarbon-perfused 23 gauge three-dimensional vitrectomy for complicated diabetic tractional retinal detachment
The use of amniotic membrane in trabeculectomy for the treatment of primary open-angle glaucoma: a prospective study